Categories
Blog

Coronavirus Patent US 10,130,701 B2

Filed: July 23, 2015 | Application filed by Pirbright Institute | Source

Abstract

“The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.”

Link To Patent_US10130701-3

A61K39/215 Coronaviridae, e.g. avian infectious bronchitis virus

 

 


 

 

European Patent 3 172 319 B1  |

Date of Filing July 23, 2015

Source

Description

FIELD OF THE INVENTION

“The present invention relates to an attenuated coronavirus comprising a variant replicase gene, which causes the virus to have reduced pathogenicity.”

 

Link To European Patent _EP3172319B1

C07K14/005 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

 

 

 


 

 

 

April 2003

“This collaboration has brought together leading scientific expertise, and was established after WHO issued a global alert on SARS on 12 March 2003. The priority has been to find the cause and to develop diagnostic tests. Two laboratories in China recently joined this network of laboratories from Canada, France, Germany, Hong Kong Special Administrative Region of China, Japan, the Netherlands, Singapore, the United Kingdom, and the United States of America.”

https://www.who.int/mediacentre/news/releases/2003/pr31/en/
https://www.who.int/mediacentre/news/releases/2003/pr31/en/

Link To Source

 

 


 

WHO Draft Landscape of Covid 19 Candidate Vaccines

 

March 2020_novel-coronavirus-landscape-ncov

 

October 2020 novel-coronavirus-landscape-covid-19cc0232c16129498983a6a0e30ca94000

 

December 2020Novel-Coronavirus_Landscape_COVID-19

 

DISCLAIMER:

” WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.”

 

 

 


 

 

 

Report of the WHO-China Joint Mission on Coronavirus Disease

February  2020

Link To_who-china-joint-mission-on-covid-19—final-report-